Does Ozempic cause gastroparesis?

Ozempic and other GLP-1 drugs slow down how fast your stomach empties. That is not a glitch. It is part of how the drug works, and it is also the source of one of the most confusing questions in weight-loss medicine right now: does that slowing ever cross the line into gastroparesis, the condition people online call "stomach paralysis"? The honest answer is that the drugs clearly delay gastric emptying, a small number of people develop persistent symptoms severe enough to be diagnosed as gastroparesis, and the data on how often that happens are messier than either the lawsuit ads or the drug makers want to admit.

This article walks through what gastroparesis actually is, how Ozempic changes stomach function, what the real evidence shows about risk, and how to tell ordinary side effects from something that needs a doctor. We grade the strength of each claim plainly, including the places where the science is thin.

What gastroparesis actually means

Gastroparesis means "stomach paralysis" in plain language, but the medical definition is narrower. It is a condition where the stomach empties food into the small intestine far too slowly without any physical blockage causing it. The classic symptoms are nausea, vomiting (sometimes of food eaten hours earlier), early fullness, bloating, and upper-belly pain.

The key point most headlines skip: a real gastroparesis diagnosis is not made on symptoms alone. It requires an objective test, usually a gastric emptying study (scintigraphy), where you eat a meal tagged with a tiny amount of radioactive tracer and a scanner measures how much is still in your stomach at two and four hours. If more than 10 percent remains at four hours, that meets the threshold for delayed emptying. Without that test, "gastroparesis" is just a symptom pattern that could have many causes.

This distinction matters enormously for Ozempic, because the drug is designed to slow emptying. So the real question is not "does Ozempic delay gastric emptying" (it does, by design) but "does it cause a lasting, abnormal slowing that persists and causes harm?"

There is also a problem of language. In ordinary speech, "stomach paralysis" sounds like the stomach has stopped moving entirely. That almost never happens. Even in true gastroparesis the stomach still works, just sluggishly and unevenly. The dramatic phrase has spread through social media and legal advertising, and it makes a measurable slowing sound like an organ has shut down. Keeping the precise definition in mind helps you read the headlines without panic.

Two different things that get blurred together

Term	What it means	Caused by Ozempic?
Delayed gastric emptying	Stomach empties slower than normal, measurable on a test	Yes, this is the intended mechanism
GI side effects (nausea, vomiting, fullness)	Symptoms from that slowing, usually early in treatment	Common, usually fade with time
Gastroparesis	A clinical diagnosis of persistent, abnormal slow emptying confirmed by testing	Reported, but how often is genuinely uncertain
"Stomach paralysis"	A media and lawsuit term, not a precise medical one	Often used loosely for any of the above

If you only remember one thing: slow emptying is expected, severe lasting gastroparesis is the rare and disputed part.

How Ozempic slows the stomach

Ozempic is semaglutide, a GLP-1 receptor agonist. GLP-1 is a hormone your gut already makes after you eat. The drug mimics it at much higher, steadier levels. One of GLP-1's normal jobs is to put the brakes on the stomach so food moves into the intestine in a controlled way. That braking does three things that help with weight and blood sugar: it keeps you full longer, blunts the post-meal blood sugar spike, and reduces appetite signals to the brain.

Studies that measure emptying directly confirm the effect is real. Early in treatment, a tagged solid meal can sit in the stomach noticeably longer than it would without the drug. That is the mechanism doing its job. The trouble is that the same braking that creates fullness also creates nausea, bloating, and occasional vomiting when food backs up, especially after large or fatty meals.

The slowing is not only about the stomach. GLP-1 receptors sit throughout the gut and the nervous system. The drug appears to dampen the speed of the whole digestive tract, not just the stomach, and it also acts on appetite centers in the brain. That is why some people feel full on a few bites and lose interest in food entirely. The same wiring that produces those benefits also produces the constipation, reflux, and burping that many users report. In other words, the unwanted effects and the wanted effects come from the same switch. You cannot fully separate them, only manage the dose and the meals so the balance lands in your favor.

It also helps to know that solid food and liquids behave differently. The slowing hits solid, fatty meals hardest, while clear liquids tend to pass through closer to normal. This is why clinicians often suggest lighter, lower-fat meals during dose increases, and why a clear-liquid diet is recommended before sedation. The stomach handles thin liquids far more easily than a heavy meal sitting on a slowed system.

The tolerance effect most people do not hear about

Here is a piece of the science that complicates the "Ozempic causes gastroparesis" story: the slowing effect tends to fade with continued use. This is called tachyphylaxis. Because the GLP-1 receptors are stimulated constantly by a long-acting drug, they become less responsive over weeks.

Shorter studies (roughly 8 to 16 weeks) tend to show clear delayed emptying. But trials running longer often show the delay shrinking back toward normal. In one body of work, the high 2.4 mg weekly dose used for weight loss showed little measurable emptying delay at 20 weeks, likely because tolerance had set in. The American Journal of Gastroenterology meta-analysis of emptying studies concluded the overall delay is, at most, mild to moderate, with unclear clinical significance for most people (Hiramoto et al., 2024).

This cuts both ways. It is reassuring that the slowing usually does not get worse over time. But it also makes it harder to explain the cases where symptoms persist for months or do not resolve after stopping the drug.

The actual evidence on gastroparesis risk

This is where honesty matters most, because the evidence is genuinely mixed and none of it is airtight.

The study everyone cites

The single most-cited paper is a 2023 retrospective cohort study in JAMA by Sodhi and colleagues. It used insurance-claims data from millions of patients and compared people taking GLP-1 drugs for weight loss against people taking an older weight-loss drug (bupropion-naltrexone). It found GLP-1 use was associated with a higher risk of gastroparesis, bowel obstruction, and pancreatitis (Sodhi et al., JAMA 2023).

That sounds damning until you read the limits, which the authors themselves flagged:

It is based on billing codes, not confirmed gastric emptying tests. A "gastroparesis" code can be entered for symptoms that were never objectively confirmed.
It is observational. It shows association, not proof of cause. People drawn to GLP-1 drugs may differ from those on the comparison drug in ways the data cannot fully adjust for.
The absolute numbers were small. Even with a raised relative risk, gastroparesis was an uncommon event in both groups.

So the JAMA study is a real signal worth taking seriously, but it is far from a clean demonstration that Ozempic causes gastroparesis at high rates.

Why a "gastroparesis code" can mislead

It is worth slowing down on the billing-code issue, because it shapes almost every claims study and lawsuit. When a doctor sees a patient with nausea, vomiting, and fullness on Ozempic, they need a diagnosis code to bill the visit. A gastroparesis code is an easy fit even when no emptying test was ever ordered. So the code can capture the drug's expected slowing, ordinary GI side effects, or a true confirmed condition, all under one label. Researchers cannot tell these apart from the data. This is called misclassification, and it tends to inflate the apparent number of cases. It does not mean the signal is fake. It means the signal is blurry, and anyone quoting a precise "X-fold increase" should be read with that blur in mind.

What the controlled trials and physiology studies show

The studies that actually measured emptying, rather than counting codes, paint a milder picture. Across these trials the average delay is real but modest, and it tends to shrink with time. The detailed physiology reviews reach a similar conclusion: GLP-1 drugs reliably slow the stomach, the effect is largest at the start and after big meals, and for the great majority of users it does not progress into a disabling condition (Clinical Consequences of Delayed Gastric Emptying, JCEM 2024). The gap between the alarming claims-based numbers and the calmer measurement-based numbers is the heart of why this topic is so contested. Neither side is lying; they are measuring different things.

Grading the evidence by question

Question	What the evidence shows	Strength of evidence
Does Ozempic delay gastric emptying?	Yes, measured directly in multiple trials	Strong
Does that delay usually fade over months?	Yes, tachyphylaxis is well documented	Moderate to strong
Does Ozempic raise the relative risk of a gastroparesis diagnosis?	One large claims study says yes	Weak to moderate (observational, coded)
How common is true, confirmed gastroparesis?	Genuinely unknown; no high-quality rate exists	Very weak / data gap
Does the slowing persist after stopping the drug?	A handful of case reports suggest it can in some people	Very weak (anecdotal)
Does delayed emptying raise surgical aspiration risk?	Plausible and taken seriously by anesthesiologists	Moderate, evolving

The most important row is the one with no good answer: nobody has a reliable, test-confirmed rate of how often Ozempic causes lasting gastroparesis. The pivotal weight-loss and diabetes trials reported nausea and vomiting in a sizable share of users, but they did not systematically run emptying studies, so they cannot tell us the true gastroparesis rate.

What the FDA label says, and does not say

In January 2025 the Ozempic label was updated. It now states the drug delays gastric emptying and is "not recommended in patients with severe gastroparesis." Crucially, the label does not state that Ozempic causes gastroparesis. It treats pre-existing severe gastroparesis as a reason to avoid the drug, which is different from naming the drug as a cause (FDA Ozempic Prescribing Information, 2025). The label also records that severe GI reactions occurred more often on Ozempic than placebo in trials, but at low single-digit percentages.

You can review the full regulatory history through the FDA Drugs@FDA Ozempic record.

The lawsuits are not evidence of causation

By late 2025, thousands of claims over GLP-1 drugs and gastroparesis had been consolidated into federal litigation. That is real, but a lawsuit count is a measure of legal activity and marketing, not of medical causation. Notably, a court order in 2025 required plaintiffs to back gastroparesis claims with an actual gastric emptying study performed when symptoms occurred. That requirement exists precisely because so many "stomach paralysis" claims rested on symptoms without objective testing. Treat litigation numbers as a flag to investigate, not as proof.

Why surgery is the clearest real-world concern

If there is one place where Ozempic's stomach-slowing has clear, documented clinical weight, it is anesthesia. A stomach that empties slowly may still hold food even after the standard pre-surgery fasting window. Under anesthesia, retained stomach contents can be regurgitated and inhaled into the lungs, called pulmonary aspiration, which is dangerous.

In June 2023, the American Society of Anesthesiologists issued guidance suggesting patients hold weekly GLP-1 drugs for about a week before elective procedures (ASA, 2023). The evidence behind that first guidance was thin, mostly case reports. By October 2024, a multi-society update walked it back: most patients can continue their GLP-1 drug, with individualized, risk-based steps such as a clear-liquid diet the day before and gastric ultrasound when in doubt (ASA multi-society guidance, 2024).

The practical takeaway: tell every anesthesiologist, surgeon, dentist doing sedation, and endoscopist that you take a GLP-1 drug. Let them decide on holding it. Do not stop on your own without asking, and do not hide it.

One reason the guidance softened is that real-world outcomes turned out better than the early case reports feared. As more procedures were done on patients taking GLP-1 drugs, serious aspiration events stayed rare, and the blanket "hold for a week" rule started to look like overkill that risked blood-sugar swings and missed doses. The current approach is to sort patients by risk: someone with active nausea, vomiting, or a recent dose increase gets more caution than someone tolerating a stable dose well. For most stable users, a clear-liquid day before the procedure plus an honest conversation is enough. The broad collection of emptying-and-aspiration research is searchable through PubMed.

Telling normal side effects from a real problem

Most GI symptoms on Ozempic are the expected, manageable kind that ease over the first weeks. A smaller set of signs suggests the slowing has become a genuine problem.

Pattern	Likely interpretation	Action
Mild nausea, fullness, less appetite in first weeks	Expected mechanism	Smaller meals, lower fat, ride it out
Symptoms that fade as weeks pass	Normal tolerance developing	Continue, monitor
Vomiting undigested food eaten many hours earlier	Possible significant retention	Call your prescriber
Persistent vomiting, dehydration, no urine, dizziness	Red flag	Urgent medical care
Severe, constant belly pain with bloating, no gas or stool	Possible obstruction or ileus	Emergency care
Symptoms continuing for months after stopping the drug	Needs a gastroparesis workup	Ask for a gastric emptying study

Eating habits change the picture a lot. Large, greasy, high-fiber meals overload a slow stomach. Smaller meals, more protein, less fat, and staying upright after eating all reduce symptoms. For broader symptom management, see our evidence-based tips for managing Ozempic nausea and the full GLP-1 side effects guide.

How to lower your risk

You cannot fully remove the chance of GI trouble, but you can stack the odds in your favor.

Titrate slowly. Most severe GI side effects cluster around dose increases. Moving up gradually, and not rushing to the highest dose, gives your gut time to adjust.
Change how you eat. Smaller portions, more protein, less fat and fried food, and not lying down right after meals all ease a slow stomach.
Stay hydrated. Vomiting and reduced intake can cause dehydration fast, which makes everything worse.
Flag any history of gastroparesis or serious GI disease before starting. If you already have gastroparesis, the label advises against the drug.
Always disclose the drug before any sedation or surgery.
Do not ignore food vomited hours after eating. That specific symptom points toward real retention and deserves a prompt call.

If side effects are intolerable despite these steps, you are not stuck. Dose reduction, switching agents, or stopping are all options. See our overview of alternatives for people who cannot tolerate Ozempic.

How the drugs compare on stomach slowing

People often ask which GLP-1 drug is "safest" for the stomach. The honest answer is that all of them slow emptying because that is part of the shared mechanism, and head-to-head gastroparesis data are thin. What we can compare is the general GI-tolerability picture and dosing, while being clear these are broad patterns, not proof one drug spares you from gastroparesis.

Drug (active ingredient)	Class	Stomach-slowing profile	Notes
Ozempic / Wegovy (semaglutide)	GLP-1 only	Clear early delay, fades with tolerance	Most-studied; the focus of most gastroparesis claims
Mounjaro / Zepbound (tirzepatide)	GLP-1 + GIP	Similar slowing; high GI side-effect rates in trials	Dual mechanism; emptying data still maturing
Rybelsus (oral semaglutide)	GLP-1 only	Same active drug, taken daily by pill	Lower peak levels per dose than injection
Trulicity (dulaglutide)	GLP-1 only	Slowing present, often milder reports	Older agent, long track record
Saxenda (liraglutide)	GLP-1 only	Daily dosing; slowing documented	Shorter-acting than weekly drugs

The pattern across the class is consistent: every one of them can slow the stomach, GI side effects cluster early and around dose increases, and none has been shown to carry zero gastroparesis risk. Tolerability is individual. Some people who struggle on one agent do fine on another, which is why switching is a reasonable step before quitting entirely.

Who should be more cautious

The drug is not equally suited to everyone. Caution is warranted if you:

Already carry a gastroparesis diagnosis, especially severe (the label advises against use).
Have diabetic gastroparesis, since diabetes itself is a leading cause and the effects may compound.
Have a history of bowel obstruction or major abdominal surgery with adhesions.
Are prone to severe dehydration or have kidney disease that dehydration could worsen.
Take other medications whose absorption could be thrown off by slower emptying.

None of these are absolute bans for most people, but they are reasons for a careful conversation with a prescriber rather than a quick telehealth checkbox. For how gastroparesis fits alongside other risks, our complete 2026 review of Ozempic side effects and the pancreatitis evidence review cover the neighboring concerns.

The bottom line

Ozempic slows gastric emptying. That is not in dispute and it is the whole point of the drug. For most people that slowing causes manageable nausea and fullness that ease over weeks as tolerance builds. A real diagnosis of gastroparesis, the lasting, test-confirmed kind, appears to be uncommon, but the truth is we lack a solid number because the big trials never ran the tests that would give one. The strongest safety signal sits with one observational claims study and a cluster of lawsuits, neither of which proves the drug routinely causes stomach paralysis.

So the fair summary is this: Ozempic does not "paralyze" the stomach in most users, it temporarily slows it, the slowing usually fades, and a small number of people develop persistent symptoms that deserve real testing rather than assumptions. If you vomit food eaten hours ago, cannot stay hydrated, or have symptoms that linger after stopping, push for a gastric emptying study and a proper workup.

Frequently Asked Questions

Is gastroparesis from Ozempic permanent?

For most people, the slowing is temporary and eases as the body adjusts, and symptoms typically improve after stopping the drug. A small number of case reports describe symptoms lasting longer, but high-quality data on permanent gastroparesis after Ozempic do not exist. If symptoms persist months after stopping, ask for a gastric emptying study.

How common is gastroparesis with Ozempic?

Nobody has a reliable confirmed rate. Nausea and vomiting are common, affecting a large share of users early on, but those are not the same as gastroparesis. One large claims study found a raised relative risk of a gastroparesis diagnosis, but it relied on billing codes, not emptying tests, so the true rate of confirmed gastroparesis remains unknown.

What is the difference between normal Ozempic side effects and gastroparesis?

Normal side effects are nausea, fullness, and mild bloating that usually fade over weeks. A possible gastroparesis problem looks different: vomiting food eaten many hours earlier, symptoms that worsen or do not improve, and dehydration. The defining feature of true gastroparesis is abnormal delayed emptying confirmed by a gastric emptying study, not symptoms alone.

Should I stop Ozempic before surgery because of stomach paralysis risk?

Do not decide on your own. Current 2024 guidance says most patients can continue their GLP-1 drug with individualized steps like a clear-liquid diet the day before and ultrasound if there is doubt. Always tell your anesthesiologist and surgeon you take a GLP-1 drug and let them make the call.

Does switching to a different GLP-1 drug avoid gastroparesis?

All GLP-1 drugs slow gastric emptying to some degree because that is part of how they work, so no agent fully avoids the effect. Tolerability varies between people and drugs, so some patients do better after switching or lowering the dose. There is no GLP-1 drug proven to carry zero gastroparesis risk.

This article is for general education only and is not medical advice. Talk to a qualified clinician before starting, stopping, or changing any medication.

Key sources: Sodhi et al., JAMA 2023 (PMID 37796527) · Hiramoto et al., Am J Gastroenterol 2024 gastric emptying meta-analysis (PMID 38634551) · Clinical Consequences of Delayed Gastric Emptying, JCEM 2024 (PMID 39418085) · FDA Ozempic Prescribing Information, 2025 · FDA Drugs@FDA Ozempic record · ASA preoperative GLP-1 guidance, 2023 · ASA multi-society GLP-1 guidance update, 2024 · PubMed: GLP-1 delayed gastric emptying and aspiration